Top

Published in:

01-08-2020 | Atrial Fibrillation | Review

Natriuretic peptides: biomarkers for atrial fibrillation management

Authors: Alireza Sepehri Shamloo, Andreas Bollmann, Nikolaos Dagres, Gerhard Hindricks, Arash Arya

Published in: Clinical Research in Cardiology | Issue 8/2020

Abstract

In clinical practice, atrial fibrillation (AF) is known as the most common sustained arrhythmia. Therefore, identification of individuals at risk of AF development/recurrence or its associated complications has emerged as a hot topic in the field of cardiology. Recently, several biomarkers have been introduced to predict AF and its consequences; however, use of biomarkers in AF management has not been highly recommended by guidelines yet. While utilization of natriuretic peptides (NPs) including brain (B-type) NPs (BNPs) in heart failure management has been well established, their use in relation to AF has not been fully understood. Accordingly, this review article aimed at presenting an overview of the role of NPs in predicting AF development/recurrence as well as its complications and making suggestions for their use in management of patients with AF in clinical settings.

Graphic abstract

Available only for authorised users

Hong KL, Glover BM (2018) The impact of lifestyle intervention on atrial fibrillation. Curr Opin Cardiol 33(1):14–19CrossRef

Berge T, Brynildsen J, Larssen HKN, Onarheim S, Jenssen GR, Ihle-Hansen H, Christophersen IE, Myrstad M, Rosjo H, Smith P, Tveit A (2017) Systematic screening for atrial fibrillation in a 65-year-old population with risk factors for stroke: data from the akershus cardiac examination 1950 study. Europace 00:1–7. https://doi.org/10.1093/europace/eux293 CrossRef

Guerra F, Brambatti M, Nieuwlaat R, Marcucci M, Dudink E, Crijns H, Matassini MV, Capucci A (2017) Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey. Europace 19(12):1922–1929. https://doi.org/10.1093/europace/eux205 CrossRefPubMed

Zimetbaum P (2017) Atrial fibrillation. Ann Intern Med 166(5):33–48. https://doi.org/10.7326/aitc201703070 CrossRef

Dagres N, Chao TF, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, Bunch TJ, Chen LY, Chen SA, Darrieux F, de Paola A, Fauchier L, Goette A, Kalman J, Kalra L, Kim YH, Lane DA, Lip GYH, Lubitz SA, Marquez MF, Potpara T, Pozzer DL, Ruskin JN, Savelieva I, Teo WS, Tse HF, Verma A, Zhang S, Chung MK, Group ESCSD (2018) European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace 20(9):1399–1421. https://doi.org/10.1093/europace/euy046 CrossRefPubMedPubMedCentral

Wintgens L, Romanov A, Phillips K, Ballesteros G, Swaans M, Folkeringa R, Garcia-Bolao I, Pokushalov E, Boersma L (2018) Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry. Europace 20(11):1783–1789. https://doi.org/10.1093/europace/euy025 CrossRefPubMed

Sepehri Shamloo A, Dagres N, Mussigbrodt A, Stauber A, Kircher S, Richter S, Dinov B, Bertagnolli L, Husser-Bollmann D, Bollmann A, Hindricks G, Arya A (2019) Atrial fibrillation and cognitive impairment: new insights and future directions. Heart Lung Circ. https://doi.org/10.1016/j.hlc.2019.05.185 CrossRefPubMed

Wakula P, Neumann B, Kienemund J, Thon-Gutschi E, Stojakovic T, Manninger M, Scherr D, Scharnagl H, Kapl M, Pieske B, Heinzel FR (2017) CHA2DS2-VASc score and blood biomarkers to identify patients with atrial high-rate episodes and paroxysmal atrial fibrillation. Europace 19(4):544–551. https://doi.org/10.1093/europace/euw101 CrossRefPubMed

Reihani H, Sepehri Shamloo A, Keshmiri A (2018) Diagnostic Value of D-dimer in acute myocardial infarction among patients with suspected acute coronary syndrome. Cardiol Res 9(1):17–21. https://doi.org/10.14740/cr620w CrossRefPubMedPubMedCentral

10.

Matusik PT, Malecka B, Lelakowski J, Undas A (2019) Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01522-x CrossRefPubMedPubMedCentral

11.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210 CrossRefPubMed

12.

Dan GA, Iliodromitis K, Scherr D, Marin F, Lenarczyk R, Estner HL, Kostkiewicz M, Dagres N, Lip GYH (2018) Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. Europace 20(8):1382–1387. https://doi.org/10.1093/europace/euy094 CrossRefPubMed

13.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA (2019) The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01513-y CrossRefPubMedPubMedCentral

14.

Tseluyko V, Salem FB, Matuzok O (2019) NT-proBNP level as a predictor of atrial fibrillation in patients with acute coronary syndrome. Emerg Med 2(97):101–107. https://doi.org/10.22141/2224-0586.2.97.2019.161650 CrossRef

15.

Sramko M, Wichterle D, Melenovsky V, Franekova J, Clemens M, Fukunaga M, Kautzner J (2019) Independent effect of atrial fibrillation on natriuretic peptide release. Clin Res Cardiol 108(2):142–149. https://doi.org/10.1007/s00392-018-1332-1 CrossRefPubMed

16.

Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB (2013) N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 61(22):2274–2284. https://doi.org/10.1016/j.jacc.2012.11.082 CrossRefPubMed

17.

Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA (2009) N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the cardiovascular health study. Circulation 120(18):1768–1774. https://doi.org/10.1161/circulationaha.109.873265 CrossRefPubMedPubMedCentral

18.

Svennberg E, Lindahl B, Berglund L, Eggers KM, Venge P, Zethelius B, Rosenqvist M, Lind L, Hijazi Z (2016) NT-proBNP is a powerful predictor for incident atrial fibrillation—validation of a multimarker approach. Int J Cardiol 223:74–81. https://doi.org/10.1016/j.ijcard.2016.08.001 CrossRefPubMed

19.

Li L, Selvin E, Lutsey PL, Hoogeveen RC, O'Neal WT, Soliman EZ, Chen LY, Alonso A (2018) Association of N-terminal pro B-type natriuretic peptide (NT-proBNP) change with the risk of atrial fibrillation in the ARIC cohort. Am Heart J 204:119–127. https://doi.org/10.1016/j.ahj.2018.07.008 CrossRefPubMedPubMedCentral

20.

Sinner MF, Stepas KA, Moser CB, Krijthe BP, Aspelund T, Sotoodehnia N, Fontes JD, Janssens AC, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Vasan RS, Wang TJ, Agarwal SK, McManus DD, Franco OH, Yin X, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kaab S, Couper D, Harris TB, Astor BC, Ballantyne CM, Hoogeveen RC, Arai AE, Soliman EZ, Ellinor PT, Stricker BH, Gudnason V, Heckbert SR, Pencina MJ, Benjamin EJ, Alonso A (2014) B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace 16(10):1426–1433. https://doi.org/10.1093/europace/euu175 CrossRefPubMedPubMedCentral

21.

Engdahl J, Svennberg E, Friberg L, Al-Khalili F, Frykman V, Kemp Gudmundsdottir K, Fredriksson T, Rosenqvist M (2017) Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design. Europace 19(2):297–302. https://doi.org/10.1093/europace/euw319 CrossRefPubMed

22.

Svennberg E, Henriksson P, Engdahl J, Hijazi Z, Al-Khalili F, Friberg L, Frykman V (2017) N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation. Heart 103(16):1271–1277. https://doi.org/10.1136/heartjnl-2016-310236 CrossRefPubMed

23.

Ghazal F, Theobald H, Rosenqvist M, Al-Khalili F (2019) Assessment of N-terminal pro-B-type natriuretic peptide level in screening for atrial fibrillation in primary health care. PLoS ONE 14(2):e0212974. https://doi.org/10.1371/journal.pone.0212974 CrossRefPubMedPubMedCentral

24.

Cai GL, Chen J, Hu CB, Yan ML, Xu QH, Yan J (2014) Value of plasma brain natriuretic peptide levels for predicting postoperative atrial fibrillation: a systemic review and meta-analysis. World J Surg 38(1):51–59. https://doi.org/10.1007/s00268-013-2284-2 CrossRefPubMed

25.

Simmers D, Potgieter D, Ryan L, Fahrner R, Rodseth RN (2015) The use of preoperative B-type natriuretic peptide as a predictor of atrial fibrillation after thoracic surgery: systematic review and meta-analysis. J Cardiothorac Vasc Anesth 29(2):389–395. https://doi.org/10.1053/j.jvca.2014.05.015 CrossRefPubMed

26.

Pu Z, Qi X, Xue T, Liu Z, Wu Y (2019) B-type natriuretic peptide and other risk factors for predicting postoperative atrial fibrillation after thoracic surgery. Thorac Cardiovasc Surg 67(2):120–124. https://doi.org/10.1055/s-0037-1609037 CrossRefPubMed

27.

Carrera P, Thongprayoon C, Cheungpasitporn W, Iyer VN, Moua T (2016) Epidemiology and outcome of new-onset atrial fibrillation in the medical intensive care unit. J Crit Care 36:102–106. https://doi.org/10.1016/j.jcrc.2016.06.032 CrossRefPubMed

28.

Augusto JB, Fernandes A, Freitas PT, Gil V, Morais C (2018) Predictors of de novo atrial fibrillation in a non-cardiac intensive care unit. Rev Bras Ter Intensiva 30(2):166–173. https://doi.org/10.5935/0103-507X.20180022 CrossRefPubMedPubMedCentral

29.

Chokengarmwong N, Yeh DD, Chang Y, Ortiz LA, Kaafarani HMA, Fagenholz P, King DR, DeMoya M, Butler K, Lee J, Velmahos G, Januzzi JL, Lee-Lewandrowski E, Lewandrowski K (2017) Elevated admission N-terminal pro-brain natriuretic peptide level predicts the development of atrial fibrillation in general surgical intensive care unit patients. J Trauma Acute Care Surg 83(3):485–490. https://doi.org/10.1097/ta.0000000000001552 CrossRefPubMed

30.

Philipson DJ, Rader F, Siegel RJ (2019) Risk factors for atrial fibrillation in hypertrophic cardiomyopathy. Eur J Prev Cardiol:2047487319828474. doi:10.1177/2047487319828474

31.

Tuluce K, Yakar Tuluce S, Kahya Eren N, Kocabas U, Akyildiz Akcay F, Gunduz R, Akyildiz ZI, Ergene O (2016) Predictors of future atrial fibrillation development in patients with hypertrophic cardiomyopathy: a prospective follow-up study. Echocardiography 33(3):379–385. https://doi.org/10.1111/echo.13093 CrossRefPubMed

32.

Tuluce K, Ozerkan F, Yakar Tuluce S, Yavuzgil O, Gurgun C, Bilgin M, Kahya Eren N, Kocabas U, Nalbantgil S, Soydas Cinar C (2015) Relationships between P wave dispersion, atrial electromechanical delay, left atrial remodeling, and NT-proBNP levels, in patients with hypertrophic cardiomyopathy. Cardiol J 22(1):94–100. https://doi.org/10.5603/CJ.a2014.0025 CrossRefPubMed

33.

Gao X, Zeng R, Liao P, Zhu H, Zhang M (2016) Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis. Scand J Clin Lab Invest 76(6):460–464. https://doi.org/10.1080/00365513.2016.1199048 CrossRefPubMed

34.

De With RR, Marcos EG, Van Gelder IC, Rienstra M (2018) Atrial fibrillation progression and outcome in patients with young-onset atrial fibrillation. Europace 20(11):1750–1757. https://doi.org/10.1093/europace/euy028 CrossRefPubMed

35.

Zeemering S, Lankveld TAR, Bonizzi P, Limantoro I, Bekkers S, Crijns H, Schotten U (2018) The electrocardiogram as a predictor of successful pharmacological cardioversion and progression of atrial fibrillation. Europace 20(7):e96–e104. https://doi.org/10.1093/europace/eux234 CrossRefPubMed

36.

Dudink E, Erkuner O, Berg J, Nieuwlaat R, de Vos CB, Weijs B, Capucci A, Camm AJ, Breithardt G, Le Heuzey JY, Luermans J, Crijns H (2018) The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey. Europace 20(6):929–934. https://doi.org/10.1093/europace/eux217 CrossRefPubMed

37.

Buttner P, Schumacher K, Dinov B, Zeynalova S, Sommer P, Bollmann A, Husser D, Hindricks G, Kornej J (2018) Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: association with atrial fibrillation progression phenotypes. Heart Rhythm 15(8):1132–1137. https://doi.org/10.1016/j.hrthm.2018.03.021 CrossRefPubMed

38.

Inohara T, Kim S, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP (2019) B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart 105(5):370–377. https://doi.org/10.1136/heartjnl-2018-313642 CrossRefPubMed

39.

Stanciu AE, Vatasescu RG, Stanciu MM, Serdarevic N, Dorobantu M (2018) The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine 103:63–68. https://doi.org/10.1016/j.cyto.2017.12.026 CrossRefPubMed

40.

Clarnette JA, Brooks AG, Mahajan R, Elliott AD, Twomey DJ, Pathak RK, Kumar S, Munawar DA, Young GD, Kalman JM, Lau DH, Sanders P (2018) Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis. Europace 20(Fi_3):f366–f376. https://doi.org/10.1093/europace/eux297 CrossRefPubMed

41.

Fink T, Metzner A, Willems S, Eckardt L, Ince H, Brachmann J, Spitzer SG, Deneke T, Schmitt C, Hochadel M, Senges J, Rillig A (2019) Procedural success, safety and patients satisfaction after second ablation of atrial fibrillation in the elderly: results from the german ablation registry. Clin Res Cardiol 108(12):1354–1363. https://doi.org/10.1007/s00392-019-01471-5 CrossRefPubMed

42.

Yao Y, Yao W, Bai R, Lu ZH, Tang RB, Long DY, Jiang CX, Sang CH, Zhang JQ, Yu RH, Du X, Liu XH, Dong JZ, Ma CS (2017) Plasma homocysteine levels predict early recurrence after catheter ablation of persistent atrial fibrillation. Europace 19(1):66–71. https://doi.org/10.1093/europace/euw081 CrossRefPubMed

43.

Fiala M, Bulkova V, Sknouril L, Nevralova R, Toman O, Januska J, Spinar J, Wichterle D (2017) Functional improvement after successful catheter ablation for long-standing persistent atrial fibrillation. Europace 19(11):1781–1789. https://doi.org/10.1093/europace/euw282 CrossRefPubMed

44.

Sepehri Shamloo A, Dagres N, Dinov B, Sommer P, Husser-Bollmann D, Bollmann A, Hindricks G, Arya A (2019) Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? a systematic review and meta-analysis. Int J Cardiol Heart Vasc 22:132–138. https://doi.org/10.1016/j.ijcha.2019.01.003 CrossRefPubMedPubMedCentral

45.

Das M, Loveday JJ, Wynn GJ, Gomes S, Saeed Y, Bonnett LJ, Waktare JEP, Todd DM, Hall MCS, Snowdon RL, Modi S, Gupta D (2017) Ablation index, a novel marker of ablation lesion quality: prediction of pulmonary vein reconnection at repeat electrophysiology study and regional differences in target values. Europace 19(5):775–783. https://doi.org/10.1093/europace/euw105 CrossRefPubMed

46.

Kapur S, Kumar S, John RM, Stevenson WG, Tedrow UB, Koplan BA, Epstein LM, MacRae CA, Michaud GF (2018) Family history of atrial fibrillation as a predictor of atrial substrate and arrhythmia recurrence in patients undergoing atrial fibrillation catheter ablation. Europace 20(6):921–928. https://doi.org/10.1093/europace/eux107 CrossRefPubMed

47.

Kim TH, Lee JS, Uhm JS, Joung B, Lee MH, Pak HN (2018) High circulating adiponectin level is associated with poor clinical outcome after catheter ablation for paroxysmal atrial fibrillation. Europace 20(8):1287–1293. https://doi.org/10.1093/europace/eux173 CrossRefPubMed

48.

Mesquita J, Ferreira AM, Cavaco D, Moscoso Costa F, Carmo P, Marques H, Morgado F, Mendes M, Adragao P (2018) Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure-ATLAS score. Europace 20(Fi_3):f428–f435. https://doi.org/10.1093/europace/eux265 CrossRefPubMed

49.

Kosich F, Schumacher K, Potpara T, Lip GY, Hindricks G, Kornej J (2019) Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation. Clin Cardiol 42(2):320–329CrossRef

50.

Jiang H, Wang W, Wang C, Xie X, Hou Y (2017) Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation: a meta-analysis. Europace 19(3):392–400. https://doi.org/10.1093/europace/euw088 CrossRefPubMed

51.

Miake J, Kato M, Ogura K, Iitsuka K, Okamura A, Tomomori T, Tsujimoto D, Kato M, Yamamoto K (2019) Pre-ablation levels of brain natriuretic peptide are independently associated with the recurrence of atrial fibrillation after radiofrequency catheter ablation in patients with nonvalvular atrial fibrillation. Heart Vessels 34(3):517–526. https://doi.org/10.1007/s00380-018-1267-5 CrossRefPubMed

52.

Kimura T, Takatsuki S, Inagawa K, Katsumata Y, Nishiyama T, Nishiyama N, Fukumoto K, Aizawa Y, Tanimoto Y, Tanimoto K, Fukuda K (2014) Serum inflammation markers predicting successful initial catheter ablation for atrial fibrillation. Heart Lung Circ 23(7):636–643. https://doi.org/10.1016/j.hlc.2014.02.003 CrossRefPubMed

53.

Pillarisetti J, Reddy N, Biria M, Ryschon K, Nagarajan D, Murray C, Atkins D, Bommana S, Reddy MY, DiBiase L, Pimentel R, Berenbom L, Dawn B, Natale A, Lakkireddy D (2014) Elevated brain natriuretic peptide level in patients undergoing atrial fibrillation ablation: is it a predictor of failed ablation or a mere function of atrial rhythm and rate at a point in time? J Interv Card Electrophysiol 40(2):161–168. https://doi.org/10.1007/s10840-014-9898-7 CrossRefPubMed

54.

Zhang Y, Chen A, Song L, Li M, Chen Y, He B (2016) Association between baseline natriuretic peptides and atrial fibrillation recurrence after catheter ablation. Int Heart J 57(2):183–189. https://doi.org/10.1536/ihj.15-355 CrossRefPubMed

55.

Ramirez FD, Sadek MM, Boileau I, Cleland M, Nery PB, Nair GM, Redpath CJ, Green MS, Davis DR, Charron K, Henne J, Zakutney T, Beanlands RSB, Hibbert B, Wells GA, Birnie DH (2018) Evaluation of a novel cardioversion intervention for atrial fibrillation: the ottawa AF cardioversion protocol. Europace. https://doi.org/10.1093/europace/euy285 CrossRefPubMedPubMedCentral

56.

Frederiksen AS, Albertsen AE, Christesen AMS, Vinter N, Frost L, Moller DS (2018) Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin. Europace 20(7):1078–1085. https://doi.org/10.1093/europace/eux188 CrossRefPubMed

57.

Ebert M, Stegmann C, Kosiuk J, Dinov B, Richter S, Arya A, Mussigbrodt A, Sommer P, Hindricks G, Bollmann A (2018) Predictors, management, and outcome of cardioversion failure early after atrial fibrillation ablation. Europace 20(9):1428–1434. https://doi.org/10.1093/europace/eux327 CrossRefPubMed

58.

Bartkowiak R, Wozakowska-Kaplon B, Janiszewska G (2010) Plasma NT-proANP in patients with persistent atrial fibrillation who underwent successful cardioversion. Kardiol Pol 68(1):48–54PubMed

59.

Xu X, Tang Y (2017) Relationship between brain natriuretic peptide and recurrence of atrial fibrillation after successful electrical cardioversion: an updated meta-analysis. Braz J Cardiovasc Surg 32(6):530–535. https://doi.org/10.21470/1678-9741-2017-0008 CrossRefPubMedPubMedCentral

60.

Zografos T, Maniotis C, Katsivas A, Katritsis D (2014) Relationship between brain natriuretic peptides and recurrence of atrial fibrillation after successful direct current cardioversion: a meta-analysis. Pacing Clin Electrophysiol 37(11):1530–1537. https://doi.org/10.1111/pace.12477 CrossRefPubMed

61.

Raman K, Aeschbacher S, Bossard M, Hochgruber T, Zimmermann AJ, Kaufmann BA, Pumpol K, Rickenbacker P, Pare G, Conen D (2016) Whole blood gene expression differentiates between atrial fibrillation and sinus rhythm after cardioversion. PLoS ONE 11(6):e0157550. https://doi.org/10.1371/journal.pone.0157550 CrossRefPubMedPubMedCentral

62.

Kornej J, Schumacher K, Husser D, Hindricks G (2018) Biomarkers and atrial fibrillation : prediction of recurrences and thromboembolic events after rhythm control management. Herzschrittmacherther Elektrophysiol 29(2):219–227. https://doi.org/10.1007/s00399-018-0558-y CrossRefPubMed

63.

Lewicka E, Dudzinska-Gehrmann J, Dabrowska-Kugacka A, Zagozdzon P, Stepnowska E, Lizewska A, Kozlowski D, Raczak G (2015) Plasma biomarkers as predictors of recurrence of atrial fibrillation. Pol Arch Med Wewn 125(6):424–433PubMed

64.

Hylek Elaine M (2019) Biomarkers for prediction of stroke and bleeds in atrial fibrillation. Circulation 139(6):772–774. https://doi.org/10.1161/CIRCULATIONAHA.118.038635 CrossRefPubMed

65.

Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg Haeusler K, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H (2018) The 2018 EUROPEAN HEART RHYTHM ASSOCIATION PRACTICAL GUIDE on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 20(8):1231–1242. https://doi.org/10.1093/europace/euy054 CrossRefPubMed

66.

Hart RG, Pearce LA, Koudstaal PJ (2004) Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke 35(4):948–951. https://doi.org/10.1161/01.str.0000120741.34866.1d CrossRefPubMed

67.

Bai Y, Guo SD, Shantsila A, Lip GYH (2018) Modelling projections for the risks related with atrial fibrillation in East Asia: a focus on ischaemic stroke and death. Europace 20(10):1584–1590. https://doi.org/10.1093/europace/eux328 CrossRefPubMed

68.

Heidbuchel H, Dagres N, Antz M, Kuck KH, Lazure P, Murray S, Carrera C, Hindricks G, Vahanian A (2018) Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. Europace 20(12):1919–1928. https://doi.org/10.1093/europace/euy039 CrossRefPubMed

69.

Inoue S, Murakami Y, Sano K, Katoh H, Shimada T (2000) Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 6(2):92–96CrossRef

70.

Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, Valdes M, Vicente V, Lip GY (2011) Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 57(25):2496–2504. https://doi.org/10.1016/j.jacc.2010.12.033 CrossRefPubMed

71.

Cushman M, Judd SE, Howard VJ, Kissela B, Gutierrez OM, Jenny NS, Ahmed A, Thacker EL, Zakai NA (2014) N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke 45(6):1646–1650. https://doi.org/10.1161/strokeaha.114.004712 CrossRefPubMedPubMedCentral

72.

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 125(13):1605–1616. https://doi.org/10.1161/circulationaha.111.038729 CrossRef

73.

Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L (2016) The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 37(20):1582–1590. https://doi.org/10.1093/eurheartj/ehw054 CrossRefPubMedPubMedCentral

74.

Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA (2019) Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation 139(6):760–771. https://doi.org/10.1161/CIRCULATIONAHA.118.038312 CrossRefPubMedPubMedCentral

75.

Llombart V, Antolin-Fontes A, Bustamante A, Giralt D, Rost NS, Furie K, Shibazaki K, Biteker M, Castillo J, Rodriguez-Yanez M, Fonseca AC, Watanabe T, Purroy F, Zhixin W, Etgen T, Hosomi N, Jafarian Kerman SR, Sharma JC, Knauer C, Santamarina E, Giannakoulas G, Garcia-Berrocoso T, Montaner J (2015) B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. Stroke 46(5):1187–1195. https://doi.org/10.1161/strokeaha.114.008311 CrossRefPubMed

76.

Fu S, Jiao J, Guo Y, Zhu B, Luo L (2019) N-terminal pro-brain natriuretic peptide levels had an independent and added ability in the evaluation of all-cause mortality in older Chinese patients with atrial fibrillation. BMC Geriatr 19(1):56. https://doi.org/10.1186/s12877-019-1051-0 CrossRefPubMedPubMedCentral

77.

Roldan V, Vilchez JA, Manzano-Fernandez S, Jover E, Galvez J, Puche CM, Valdes M, Vicente V, Lip GY, Marin F (2014) Usefulness of N-terminal pro-B-type natriuretic peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke 45(3):696–701. https://doi.org/10.1161/strokeaha.113.003338 CrossRefPubMed

78.

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Siegbahn A, Yusuf S, Wallentin L (2014) Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart 100(15):1193–1200. https://doi.org/10.1136/heartjnl-2013-304872 CrossRefPubMed

79.

Holl MJ, van den Bos EJ, van Domburg RT, Fouraux MA, Kofflard MJ (2018) NT-proBNP is associated with mortality and adverse cardiac events in patients with atrial fibrillation presenting to the emergency department. Clin Cardiol 41(3):400–405. https://doi.org/10.1002/clc.22883 CrossRefPubMedPubMedCentral

80.

Niederdockl J, Simon A, Schnaubelt S, Schuetz N, Laggner R, Sulzgruber P, Spiel AO, Herkner H, Laggner AN, Domanovits H (2019) Cardiac biomarkers predict mortality in emergency patients presenting with atrial fibrillation. Heart 105(6):482–488. https://doi.org/10.1136/heartjnl-2018-313145 CrossRefPubMed

81.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350(7):655–663. https://doi.org/10.1056/NEJMoa031994 CrossRefPubMed

82.

Schnabel RB, Wild PS, Wilde S, Ojeda FM, Schulz A, Zeller T, Sinning CR, Kunde J, Lackner KJ, Munzel T, Blankenberg S (2014) Multiple biomarkers and atrial fibrillation in the general population. PLoS ONE 9(11):e112486. https://doi.org/10.1371/journal.pone.0112486 CrossRefPubMedPubMedCentral

83.

Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, Kronmal RA (2013) N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the multi-ethnic study of atherosclerosis: the effects of age, sex and ethnicity. Heart 99(24):1832–1836. https://doi.org/10.1136/heartjnl-2013-304724 CrossRefPubMed

84.

Kumarathurai P, Mouridsen MR, Mattsson N, Larsen BS, Nielsen OW, Gerds TA, Sajadieh A (2017) Atrial ectopy and N-terminal pro-B-type natriuretic peptide as predictors of atrial fibrillation: a population-based cohort study. Europace 19(3):364–370. https://doi.org/10.1093/europace/euw017 CrossRefPubMed

Title: Natriuretic peptides: biomarkers for atrial fibrillation management
Authors: Alireza Sepehri Shamloo
Andreas Bollmann
Nikolaos Dagres
Gerhard Hindricks
Arash Arya
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keywords: Atrial Fibrillation
Biomarkers
Published in: Clinical Research in Cardiology / Issue 8/2020
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-020-01608-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Natriuretic peptides: biomarkers for atrial fibrillation management

Abstract

Graphic abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphic abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

Outcomes in patients with dual antegrade conduction in the atrioventricular node: insights from a multicentre observational study

Simultaneous two-sided endocarditis: cardiac resynchronization leads and left atrial appendage occluder

Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study

Amplified P-wave duration predicts new-onset atrial fibrillation in patients with heart failure with preserved ejection fraction

High density mapping and catheter ablation of atrial tachycardias in adults with congenital heart disease